Table 3 Results of ORR by treatment schedule (Weekly vs. 3-Weekly) and by treatment drug (gemcitabine+docetaxel vs. gemcitabine+paclitaxel)
Treatment schedule | Treatment drug | |||
|---|---|---|---|---|
Weekly | 3-weekly | Gemcitabine + docetaxel | Gemcitabine + paclitaxel | |
(N= 117) | (N= 121) | (N= 117) | (N= 121) | |
N(%) | N(%) | N(%) | N(%) | |
Complete response (CR) | 8 (6.8) | 7 (5.8) | 6 (5.1) | 9 (7.4) |
Partial response (PR) | 51 (43.6) | 34 (28.1) | 45 (38.5) | 40 (33.1) |
Stable disease (SD) | 28 (23.9) | 50 (41.3) | 38 (32.5) | 40 (33.1) |
Progressive disease (PD) | 25 (21.4) | 16 (13.2) | 21 (17.9) | 20 (16.5) |
Not available | 1 (0.9) | 2 (1.7) | 1 (0.9) | 2 (1.7) |
Not assessed | 4 (3.4) | 12 (9.9) | 6 (5.1) | 10 (8.3) |
ORR (CR + PR) | 59 (50.4) | 41 (33.9) | 51 (43.6) | 49 (39.8) |
Odds Ratio (95% CI); p value | 0.504 (0.299-0.850); 0.010 | 0.882 (0.523-1.488); 0.639 | ||